18 Swiss biotech companies to keep an eye on
This issue of our newsletter is supported by Inpart.
Switzerland isn’t just a beautiful place with great chocolates and cheeses - it actually has a very strong biotech industry, too.
In fact, the Swiss biotech sector raised more than $2.2 billion in 2023.
Biotech companies in Switzerland are heavily invested in developing new cancer treatments and immunotherapies.
The country is also a hub for cell and gene therapy development and contributes to research on therapies targeting the aging process and age-related diseases.
This week we take a look at 18 biotech companies to keep an eye on in Switzerland.
To find out more, read the full article: “Swiss biotech going strong in 2024: 18 companies to put on your radar”
A MESSAGE FROM OUR SPONSOR INPART
The annual partnering 2030 survey is open
Inpart is dedicated to helping make biopharma partnering more accessible and efficient. Our annual survey allows biotechs to communicate to pharma companies what matters most when it comes to partnering while highlighting key trends, challenges, and changes throughout the industry.
Share your insights and play your part in shaping the future of biopharma partnering.
🔥 More noteworthy articles from this week:
With 115 funding rounds surpassing the $100 million mark in 2024, the amount of megadeals is already above last year’s 73 deals. We reached out to industry experts to find out why megadeals are ramping up in biotech and what to expect in the future.
2024 has witnessed the approval of a number of medicines, including first-in-class drugs like Rezdiffra for chronic liver disease, Duvyzat for a rare muscular disorder, and Winrevair for a rare condition that causes blood pressure in the lungs. In this article, we look at eight much-awaited drugs that have been approved by regulators.
CRISPR-Cas9’s lesser-known cousin, CRISPR-Cas13, is making headway in a number of applications, both as a diagnostic tool and as a gene therapy. We explored how CRISPR-Cas13 differs from CRISPR-Cas9, its advantages and disadvantages, and what the technology can be used for.
Emerging as a new class of drugs, radiopharmaceuticals are all the rage in cancer treatment research at present. There have also been a number of major buyouts related to these types of drugs, which have become part of a larger market trend witnessed by the radiopharmaceutical industry.
Biotechnology can be used to improve athletic performance and recovery in sports, from genetic profiling, stem cells, and wearable technologies. As the 2024 Olympic Games are approaching, we take a look at how biotech is helping to revolutionize sports performance worldwide, as well as how it could also potentially bring certain downsides and ethical concerns to the sports industry.
US-based biotech company Priovant Therapeutics is dedicated to developing novel therapies for autoimmune diseases with high morbidity and few available treatment options. This week, we have a conversation with Priovant’s CEO Benjamin Zimmer about dermatomyositis, non-infectious uveitis, current treatments, potential options, and how the company’s lead asset, brepocitinib, is making a difference.
To better grasp the interests and preferences of those immersed in biotech, we conducted a comprehensive survey a few weeks ago that unearthed valuable insights reflecting broader industry trends. Naturally, we decided we’d share the result with all of you so you can also learn from it.
With single-gene based drug target identification methods getting saturated, the scientific world is venturing beyond traditional approaches to enhance early drug discovery. Discover how multivariate analysis can help in identifying multi-gene targets and improve patient outcomes through precision medicine.
💡Enjoying these articles? Never miss a single publication of Labiotech by becoming a part of our community! Click here to join our mailing list.
Clinical, Regulatory and Market access
1wThanks for sharing!